UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________________ FORM 10-Q _____________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38042 _____________________________________ ARROWHEAD ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 6, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal first quarter ended December 31, 2023. Webcast and Conference Call and Details Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. A replay of the webcast will be available approximately two hours after the conclusion of ...

icarus666/Moment via Getty Images In my coverage of Arrowhead Pharmaceuticals (ARWR) last February, I noted that my primary problem with ARWR is a lack of focus. Just look at this pipeline: ARWR PIPELINE (ARWR WEBSITE) There are, if I am counting it right, some 16 programs in the clinic, and frankly, this is too much. Like I noted last time, they should probably have focused on getting one product through the finishing line. Then, this long-tailed pipeline would have been an asset. If you want a good tail, ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2023 Earnings Conference Call November 29, 2023 4:30 PM ET Company Participants Vince Anzalone - Vice President, Investor Relations Chris Anzalone - President & Chief Executive Officer Javier San Martin - Chief Medical Officer James Hamilton - Chief Discovery & Translational Medicine Ken Myszkowski - Chief Financial Officer Tracy Oliver - Chief Commercial Officer Patrick O'Brien - Chief Operating Officer and General Counsel Conference Call Participants Edward ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 __________________________________________________________________ FORM 10-K __________________________________________________________________ (Mark One) x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2023. o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38042 ________ ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2023 Earnings Conference Call August 7, 2023 4:30 PM ET Company Participants Vince Anzalone - Vice President, Investor Relations Chris Anzalone - President & Chief Executive Officer Javier San Martin - Chief Medical Officer James Hamilton - Chief Discovery & Translational Medicine Ken Myszkowski - Chief Financial Officer Conference Call Participants Luca Issi - RBC Capital Maury Raycroft - Jefferies Patrick Trucchio - HC Wainwright & Company Keay Nakae - Char ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________________ FORM 10-Q _____________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-38042 _____________________________________ ARROWHEAD PH ...

Financial Data and Key Metrics Changes - The net income for Q2 2023 was $48.7 million, or $0.45 per share, compared to $44.4 million, or $0.41 per share, in Q2 2022 [36] - Revenue for Q2 2023 was $146.3 million, down from $151.8 million in Q2 2022, primarily due to collaboration agreements with Takeda and GSK [36][37] - Total operating expenses decreased to $98.1 million in Q2 2023 from $110.3 million in Q2 2022, driven by reduced candidate costs and lower stock compensation expenses [38] Business Line Data and Key Metrics Changes - The company has 12 drug candidates in clinical studies, with expectations to increase to at least 14 by the end of 2023, targeting liver, lung, and CNS [5][6] - ARO-RAGE showed up to 90% knockdown in serum after two inhaled doses, indicating strong performance in the pulmonary pipeline [7][29] - ARO-APOC3 is in a Phase 3 study with expected completion in Q2 2024, and has received Fast Track designation from the FDA [14][23] Market Data and Key Metrics Changes - The company is expanding its TRiM platform to include new organ systems, including adipose tissue, with demonstrated gene silencing of over 90% in non-human primates [12] - The CNS platform is advancing with ARO-SOD1, targeting ALS caused by SOD1 mutations, with a CTA filing expected in Q3 2023 [10][35] Company Strategy and Development Direction - The company aims to grow its pipeline of RNAi therapeutics to 20 clinical stage or marketed products by 2025, focusing on multiple organ systems [6][41] - The strategy includes a healthy mix of wholly-owned and partnered programs, with recent milestone payments from partners indicating progress [16][37] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of RNAi therapeutics to address unmet medical needs across various organ systems [12][41] - The company anticipates a busy second half of 2023 with numerous opportunities to demonstrate the value of its pipeline [41] Other Important Information - The company received a $40 million milestone payment from Takeda and a $30 million milestone payment from GSK during the quarter [16][37] - Cash and investments totaled $559.8 million as of March 31, 2023, an increase from $482.3 million in September 2022 [39] Q&A Session Summary Question: Additional details on new data at the R&D day - The company will overview pulmonary programs and provide early data from MUC5AC and ARO-RAGE, along with updates on ARO-ANG3 and ARO-APOC3 [44][45] Question: Reporting on patient baseline characteristics for the PALISADE study - Management indicated that key inclusion criteria will be reviewed, but detailed baseline characteristics will not be reported until the end of the study [48] Question: Endpoints for pulmonary data reporting - Key biomarkers such as Feno and FeV1 will be measured, but the small cohorts are not powered for FeV1 [50][51] Question: Comparison of ARO-SOD1 with Tofersen - ARO-SOD1 is expected to provide better depth of gene target knockdown and longer duration of effect compared to Tofersen [56] Question: Financial impact of recent updates - The company plans to maintain its growth trajectory and is focused on finding good partners for its expanding pipeline [60]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________________ FORM 10-Q _____________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-38042 _____________________________________ ARROWHEAD P ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2023 Earnings Conference Call February 6, 2023 4:30 PM ET Company Participants Vincent Anzalone - Vice President, Investor Relations Christopher Anzalone - President and Chief Executive Officer Javier San Martin - Chief Medical Officer James Hamilton - Chief, Discovery and Translational Medicine Ken Myszkowski - Chief Financial Officer Tracy Oliver - Chief Commercial Officer Patrick O’Brien - Chief Operating Officer and General Counsel Conference Call Partici ...